Sunir Garg, MD, expresses excitement about attending AAO 2025 and focuses on several topics to be discussed. These include the benefits and potential vision risks of GLP-1 inhibitors in patients with diabetes, updated screening guidelines for hydroxychloroquine-induced eye disease, and new treatments for conditions such as macular telangiectasis.
The meeting will also cover innovative approaches, such as optogenetics, for inherited retinal diseases such as retinitis pigmentosa. Dr Garg anticipates gaining valuable insights on these developments and looks forward to sharing findings from the conference.
